Published in Medicine (Baltimore) on October 01, 2015
Acute Effects of a Flutter Device in COPD (AEFLUC) | NCT01832961
Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med (2012) 22.96
Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care (2003) 19.69
The forced oscillation technique in clinical practice: methodology, recommendations and future developments. Eur Respir J (2003) 3.21
Exhaled nitric oxide in pulmonary diseases: a comprehensive review. Chest (2010) 2.29
Comparison of the flutter device to standard chest physiotherapy in hospitalized patients with cystic fibrosis: a pilot study. Chest (1998) 2.12
Efficacy of the Flutter device for airway mucus clearance in patients with cystic fibrosis. J Pediatr (1994) 1.61
Effects of a flutter mucus-clearance device on pulmonary function test results in healthy people 85 years and older in China. Respir Care (2010) 1.40
Comparison of inspiratory and expiratory resistance and reactance in patients with asthma and chronic obstructive pulmonary disease. Thorax (2010) 1.18
Effect of airways constriction on exhaled nitric oxide. J Appl Physiol (1985) (2008) 1.18
Expiratory flow limitation detected by forced oscillation and negative expiratory pressure. Eur Respir J (2006) 1.16
Sputum rheology changes in cystic fibrosis lung disease following two different types of physiotherapy: flutter vs autogenic drainage. Chest (1998) 1.09
Current evidence and future research needs for FeNO measurement in respiratory diseases. Respir Med (2014) 1.06
Lessons learned from a randomized trial of airway secretion clearance techniques in cystic fibrosis. Pediatr Pulmonol (2010) 0.99
Effectiveness of treatment with high-frequency chest wall oscillation in patients with bronchiectasis. BMC Pulm Med (2013) 0.96
Long-term comparative trial of positive expiratory pressure versus oscillating positive expiratory pressure (flutter) physiotherapy in the treatment of cystic fibrosis. J Pediatr (2001) 0.92
Revisited physicochemical and transport properties of respiratory mucus in genotyped cystic fibrosis patients. Am J Respir Crit Care Med (1997) 0.91
Bronchial mucus transport. Respir Care (2007) 0.91
Comparison of high-frequency chest wall oscillation and oscillating positive expiratory pressure in the home management of cystic fibrosis: a pilot study. Pediatr Pulmonol (2001) 0.91
Airway clearance techniques for chronic obstructive pulmonary disease. Cochrane Database Syst Rev (2012) 0.91
Comparison of Flutter device and chest physical therapy in the treatment of cystic fibrosis pulmonary exacerbation. Pediatr Pulmonol (1999) 0.90
Chest physical therapy in patients with acute exacerbation of chronic bronchitis: effectiveness of three methods. Arch Phys Med Rehabil (2000) 0.89
[The value of physical therapy with VRP 1-Desitin ("Flutter")]. Pneumologie (1992) 0.88
Randomised crossover study of the Flutter device and the active cycle of breathing technique in non-cystic fibrosis bronchiectasis. Thorax (2002) 0.88
Effects of bronchodilators on regional lung sound distribution in patients with chronic obstructive pulmonary disease. Respiration (2013) 0.85
Clinical evaluation of oscillating positive expiratory pressure for enhancing expectoration in diseases other than cystic fibrosis. Monaldi Arch Chest Dis (1995) 0.85
Treating the small airways. Respiration (2012) 0.84
The intrapulmonary percussive ventilator and flutter device compared to standard chest physiotherapy in patients with cystic fibrosis. Clin Pediatr (Phila) (1998) 0.84
The Flutter VRP1 as an adjunct to chest physiotherapy in cystic fibrosis. Respir Med (1994) 0.84
Effects of ELTGOL and Flutter VRP1® on the dynamic and static pulmonary volumes and on the secretion clearance of patients with bronchiectasis. Rev Bras Fisioter (2012) 0.83
The application of impulse oscillation system for the evaluation of treatment effects in patients with COPD. Respir Physiol Neurobiol (2014) 0.83
Evaluation of a novel sputum clearance technique--hydro-acoustic therapy (HAT) in adult patients with cystic fibrosis: a feasibility study. Chron Respir Dis (2010) 0.81
The Flutter VRP1: a new personal pocket therapeutic device used as an adjunct to drug therapy in the management of bronchial asthma. J Investig Allergol Clin Immunol (1994) 0.81
Oscillating devices for airway clearance in people with cystic fibrosis. Cochrane Database Syst Rev (2014) 0.81
Clinical efficacy of the FLUTTER device for airway mucus clearance in patients with diffuse panbronchiolitis. Respirology (1998) 0.81
Use of flutter VRP1 in the management of patients with steroid-dependent asthma. Respiration (1994) 0.81
Effects of the flutter device on pulmonary function studies among pediatric cystic fibrosis patients. Del Med J (1999) 0.80
Flutter valve improves respiratory mechanics and sputum production in patients with bronchiectasis. Physiother Res Int (2010) 0.79
Effects of flutter and PEP mask physiotherapy on symptoms and lung function in children with cystic fibrosis. Eur Respir J (1998) 0.79
Indacaterol and tiotropium combination therapy in patients with chronic obstructive pulmonary disease. Pulm Pharmacol Ther (2014) 0.78
Use of a mucus clearance device enhances the bronchodilator response in patients with stable COPD. Chest (2002) 0.78
[Physical therapy in patients with COPD and tracheobronchial instability--comparison of 2 oscillating PEP systems (RC-Cornet, VRP1 Desitin). Results of a randommized prospective study of 90 patients]. Pneumologie (1997) 0.77
Effects of sputum oscillations and rhDNase in vitro: a combined approach to treat cystic fibrosis lung disease. Pediatr Pulmonol (1998) 0.77
Immediate changes in blood-gas tensions during chest physiotherapy with positive expiratory pressure and oscillating positive expiratory pressure in patients with cystic fibrosis. Respir Care (2006) 0.77
The influence of Flutter®VRP1 components on mucus transport of patients with bronchiectasis. Respir Med (2011) 0.76
Influence that oscillating positive expiratory pressure using predetermined expiratory pressures has on the viscosity and transportability of sputum in patients with bronchiectasis. J Bras Pneumol (2009) 0.76
Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med (2007) 47.86
Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med (2012) 22.96
Chronic obstructive pulmonary disease in non-smokers. Lancet (2009) 6.41
Decreased histone deacetylase activity in chronic obstructive pulmonary disease. N Engl J Med (2005) 6.13
Increased 8-isoprostane and interleukin-6 in breath condensate of obstructive sleep apnea patients. Chest (2002) 3.05
Isoprostanes: markers and mediators of oxidative stress. FASEB J (2004) 2.83
Histone deacetylase 2-mediated deacetylation of the glucocorticoid receptor enables NF-kappaB suppression. J Exp Med (2005) 2.72
Retracted The effects of a monoclonal antibody directed against tumor necrosis factor-alpha in asthma. Am J Respir Crit Care Med (2006) 2.72
A randomized, double-blind, placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma. Am J Respir Crit Care Med (2009) 2.56
COPD as a disease of accelerated lung aging. Chest (2009) 2.56
Regional lung deposition and bronchodilator response as a function of beta2-agonist particle size. Am J Respir Crit Care Med (2005) 2.43
Expression and activity of histone deacetylases in human asthmatic airways. Am J Respir Crit Care Med (2002) 2.40
Positional cloning of a quantitative trait locus on chromosome 13q14 that influences immunoglobulin E levels and asthma. Nat Genet (2003) 2.21
Theophylline restores histone deacetylase activity and steroid responses in COPD macrophages. J Exp Med (2004) 2.19
A molecular mechanism of action of theophylline: Induction of histone deacetylase activity to decrease inflammatory gene expression. Proc Natl Acad Sci U S A (2002) 2.17
Positional cloning of a novel gene influencing asthma from chromosome 2q14. Nat Genet (2003) 2.16
Targeting phosphoinositide-3-kinase-delta with theophylline reverses corticosteroid insensitivity in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2010) 2.06
Rhinovirus infection induces degradation of antimicrobial peptides and secondary bacterial infection in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2012) 2.06
Molecular mechanisms of corticosteroid resistance. Chest (2008) 2.06
Neutrophil chemotactic activity of sputum from patients with COPD: role of interleukin 8 and leukotriene B4. Chest (2003) 2.04
The European Respiratory Society plans its future: the 2013-2018 strategic plan. Eur Respir J (2014) 2.02
Oxidative stress-induced antibodies to carbonyl-modified protein correlate with severity of chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2011) 2.02
Release and activity of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 by alveolar macrophages from patients with chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol (2002) 2.00
Glucocorticoid receptor nuclear translocation in airway cells after inhaled combination therapy. Am J Respir Crit Care Med (2005) 1.93
p38 Mitogen-activated protein kinase-induced glucocorticoid receptor phosphorylation reduces its activity: role in steroid-insensitive asthma. J Allergy Clin Immunol (2002) 1.84
Effect of theophylline on induced sputum inflammatory indices and neutrophil chemotaxis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2002) 1.84
Impaired inhibition by dexamethasone of cytokine release by alveolar macrophages from patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2002) 1.82
Anti-inflammatory effects of resveratrol in lung epithelial cells: molecular mechanisms. Am J Physiol Lung Cell Mol Physiol (2004) 1.77
Glucocorticoids: effects on gene transcription. Proc Am Thorac Soc (2004) 1.73
Is exposure to biomass smoke the biggest risk factor for COPD globally? Chest (2010) 1.71
p38 mitogen-activated protein kinase-γ inhibition by long-acting β2 adrenergic agonists reversed steroid insensitivity in severe asthma. Mol Pharmacol (2011) 1.70
Increasing doses of inhaled corticosteroids compared to adding long-acting inhaled beta2-agonists in achieving asthma control. Chest (2008) 1.67
Nitric oxide synthase isoenzyme expression and activity in peripheral lung tissue of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2009) 1.67
Increased p21(CIP1/WAF1) and B cell lymphoma leukemia-x(L) expression and reduced apoptosis in alveolar macrophages from smokers. Am J Respir Crit Care Med (2002) 1.65
An Official American Thoracic Society/European Respiratory Society Statement: Research questions in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2015) 1.63
Inhibition of PI3Kdelta restores glucocorticoid function in smoking-induced airway inflammation in mice. Am J Respir Crit Care Med (2009) 1.59
Chronic idiopathic cough: a discrete clinical entity? Chest (2005) 1.59
Maternally imprinted microRNAs are differentially expressed during mouse and human lung development. Dev Dyn (2007) 1.57
Treatment of airway mucus hypersecretion. Ann Med (2006) 1.55
Increased exhaled cysteinyl-leukotrienes and 8-isoprostane in aspirin-induced asthma. Am J Respir Crit Care Med (2002) 1.54
Alveolar macrophage-mediated elastolysis: roles of matrix metalloproteinases, cysteine, and serine proteases. Am J Physiol Lung Cell Mol Physiol (2002) 1.53
Histone acetylase and deacetylase activity in alveolar macrophages and blood mononocytes in asthma. Am J Respir Crit Care Med (2004) 1.53
Rescue treatment in asthma. More than as-needed bronchodilation. Chest (2009) 1.52
Comparison of the effects of salmeterol and formoterol in patients with severe asthma. Chest (2002) 1.50
A protein deacetylase SIRT1 is a negative regulator of metalloproteinase-9. FASEB J (2009) 1.47
NF-kappaB and activator protein 1 response elements and the role of histone modifications in IL-1beta-induced TGF-beta1 gene transcription. J Immunol (2006) 1.46
Biomarkers of some pulmonary diseases in exhaled breath. Biomarkers (2002) 1.45
Defective glucocorticoid receptor nuclear translocation and altered histone acetylation patterns in glucocorticoid-resistant patients. J Allergy Clin Immunol (2004) 1.38
Oxidative stress in COPD. Chest (2013) 1.37
Relative corticosteroid insensitivity of peripheral blood mononuclear cells in severe asthma. Am J Respir Crit Care Med (2006) 1.37
Exhaled biomarkers. Chest (2006) 1.36
The role of oxidative stress in chronic obstructive pulmonary disease. COPD (2004) 1.33
Against the Dutch hypothesis: asthma and chronic obstructive pulmonary disease are distinct diseases. Am J Respir Crit Care Med (2006) 1.32
Burden and pathogenesis of chronic obstructive pulmonary disease. Proc Am Thorac Soc (2009) 1.28
Regulation of Th2 cytokine genes by p38 MAPK-mediated phosphorylation of GATA-3. J Immunol (2007) 1.28
Chronic obstructive pulmonary disease and lung cancer: new molecular insights. Respiration (2011) 1.28
Matrix metalloproteinase-9 expression in asthma: effect of asthma severity, allergen challenge, and inhaled corticosteroids. Chest (2002) 1.27
Increased leukotrienes in exhaled breath condensate in childhood asthma. Am J Respir Crit Care Med (2002) 1.27
A selective inhibitor of inducible nitric oxide synthase inhibits exhaled breath nitric oxide in healthy volunteers and asthmatics. FASEB J (2003) 1.27
The electronic nose in respiratory medicine. Respiration (2012) 1.23
Steroid-resistant neutrophilic inflammation in a mouse model of an acute exacerbation of asthma. Am J Respir Cell Mol Biol (2008) 1.23
CXCR3 and CCR5 chemokines in induced sputum from patients with COPD. Chest (2007) 1.22
Analysis of expired air for oxidation products. Am J Respir Crit Care Med (2002) 1.22
Activated protein C inhibits bronchial hyperresponsiveness and Th2 cytokine expression in mice. Blood (2003) 1.21
Comparison of inspiratory and expiratory resistance and reactance in patients with asthma and chronic obstructive pulmonary disease. Thorax (2010) 1.18
Decreased histone deacetylase 2 impairs Nrf2 activation by oxidative stress. Biochem Biophys Res Commun (2011) 1.18
Histone deacetylation: an important mechanism in inflammatory lung diseases. COPD (2005) 1.17
Nitrosative stress in the bronchial mucosa of severe chronic obstructive pulmonary disease. J Allergy Clin Immunol (2005) 1.17
Statins enhance the anti-inflammatory effects of inhaled corticosteroids in asthmatic patients through increased induction of indoleamine 2, 3-dioxygenase. J Allergy Clin Immunol (2010) 1.17
Glucocorticoids reverse IL-1beta-induced impairment of beta-adrenoceptor-mediated relaxation and up-regulation of G-protein-coupled receptor kinases. Br J Pharmacol (2002) 1.17
Nitration of distinct tyrosine residues causes inactivation of histone deacetylase 2. Biochem Biophys Res Commun (2009) 1.17
Analysis of exhaled breath condensate for monitoring airway inflammation. Trends Pharmacol Sci (2002) 1.16
Cytokine production by bronchoalveolar lavage T lymphocytes in chronic obstructive pulmonary disease. J Allergy Clin Immunol (2006) 1.15
Theobromine inhibits sensory nerve activation and cough. FASEB J (2004) 1.15
Exhaled leukotrienes and prostaglandins in asthma. J Allergy Clin Immunol (2002) 1.14
Alteration of adenosine receptors in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2005) 1.13
New drugs for exacerbations of chronic obstructive pulmonary disease. Lancet (2009) 1.13
Increased leukotriene B4 and interleukin-6 in exhaled breath condensate in cystic fibrosis. Am J Respir Crit Care Med (2003) 1.13
Repression of inflammatory gene expression in human pulmonary epithelial cells by small-molecule IkappaB kinase inhibitors. J Pharmacol Exp Ther (2007) 1.11
Acidic mammalian chitinase--a potential target for asthma therapy. Trends Pharmacol Sci (2004) 1.11
Beta2-agonists potentiate corticosteroid-induced neutrophil survival. COPD (2008) 1.10
Defects of protein phosphatase 2A causes corticosteroid insensitivity in severe asthma. PLoS One (2011) 1.10
Specific CXC but not CC chemokines cause elevated monocyte migration in COPD: a role for CXCR2. J Leukoc Biol (2004) 1.09
Treatment effects of low-dose theophylline combined with an inhaled corticosteroid in COPD. Chest (2010) 1.08
High levels of interleukin-6 in the exhaled breath condensate of patients with COPD. Respir Med (2003) 1.08
Effects of inhaled corticosteroids on exhaled leukotrienes and prostanoids in asthmatic children. J Allergy Clin Immunol (2004) 1.07
Restoration of corticosteroid sensitivity by p38 mitogen activated protein kinase inhibition in peripheral blood mononuclear cells from severe asthma. PLoS One (2012) 1.07
Sputum myeloperoxidase in chronic obstructive pulmonary disease. Eur J Med Res (2014) 1.07
NMR spectroscopy metabolomic profiling of exhaled breath condensate in patients with stable and unstable cystic fibrosis. Thorax (2011) 1.07
Safety of regadenoson, an adenosine A2A receptor agonist for myocardial perfusion imaging, in mild asthma and moderate asthma patients: a randomized, double-blind, placebo-controlled trial. J Nucl Cardiol (2008) 1.07
Discovery of BRL 50481 [3-(N,N-dimethylsulfonamido)-4-methyl-nitrobenzene], a selective inhibitor of phosphodiesterase 7: in vitro studies in human monocytes, lung macrophages, and CD8+ T-lymphocytes. Mol Pharmacol (2004) 1.07
Pharmacological characterization of indacaterol, a novel once daily inhaled 2 adrenoceptor agonist, on small airways in human and rat precision-cut lung slices. J Pharmacol Exp Ther (2007) 1.06
MUC5AC expression is increased in bronchial submucosal glands of stable COPD patients. Histopathology (2009) 1.06